[go: up one dir, main page]

AR065875A1 - Metodos de separacion y detecion de acetato de bacedoxifeno en composiciones farmaceuticas - Google Patents

Metodos de separacion y detecion de acetato de bacedoxifeno en composiciones farmaceuticas

Info

Publication number
AR065875A1
AR065875A1 ARP080101301A ARP080101301A AR065875A1 AR 065875 A1 AR065875 A1 AR 065875A1 AR P080101301 A ARP080101301 A AR P080101301A AR P080101301 A ARP080101301 A AR P080101301A AR 065875 A1 AR065875 A1 AR 065875A1
Authority
AR
Argentina
Prior art keywords
acetate
bacedoxifene
produce
components
filtrate
Prior art date
Application number
ARP080101301A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR065875A1 publication Critical patent/AR065875A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D53/00Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34Chemical or biological purification of waste gases
    • B01D53/92Chemical or biological purification of waste gases of engine exhaust gases
    • B01D53/94Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
    • B01D53/9445Simultaneously removing carbon monoxide, hydrocarbons or nitrogen oxides making use of three-way catalysts [TWC] or four-way-catalysts [FWC]
    • B01D53/945Simultaneously removing carbon monoxide, hydrocarbons or nitrogen oxides making use of three-way catalysts [TWC] or four-way-catalysts [FWC] characterised by a specific catalyst
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/20Air quality improvement or preservation, e.g. vehicle emission control or emission reduction by using catalytic converters
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02TCLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00Road transport of goods or passengers
    • Y02T10/10Internal combustion engine [ICE] based vehicles
    • Y02T10/12Improving ICE efficiencies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Environmental & Geological Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Combustion & Propulsion (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

Métodos para separar y detectar el acetato de bacedoxifeno de composiciones farmacéuticas que contienen una mezcla de acetato de bacedoxifeno y uno o mas de otros componentes que producen patrones de difraccion de rayos X que tienen picos deinterferencia en o cerca de los picos característicos para el acetato de bacedoxifeno. Reivindicacion 1: Un método para separar una composicion farmacéutica que comprende acetato de bacedoxifeno y uno o más de los componentes que producen patronesde difraccion de Rayos X que tienen uno o más picos de interferencia en o cerca del pico o picos característicos para el acetato de bacedoxifeno, método que comprende: (a) poner en contacto la composicion farmacéutica con un medio de extraccion paraproducir una suspension, caracterizado en que el acetato de bacedoxifeno es sustancialmente insoluble en el medio de extraccion y donde el uno o más componentes son sustancialmente solubles en el medio de extraccion; (b) filtrar la suspension paraproducir un filtrado y un filtrando, caracterizado en que el uno o más componentes están sustancialmente contenidos en el filtrado; y (c). secar el filtrando para obtener una composicion sustancialmente libre del uno o más componentes que producenpatrones de difraccion de Rayos X que tienen uno o más picos de interferencia. Reivindicacion 6: el método de acuerdo con cualquiera de las reivindicaciones 1-5 caracterizado en que el acetato de bacedoxifeno es acetato de bacedoxifeno forma A y/oacetato de bacedoxifeno forma B. Reivindicacion 34: el método de acuerdo con la reivindicacion 33, caracterizado en que la composicion farmacéutica también comprende estrogenos conjugados.
ARP080101301A 2007-03-30 2008-03-28 Metodos de separacion y detecion de acetato de bacedoxifeno en composiciones farmaceuticas AR065875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90911307P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
AR065875A1 true AR065875A1 (es) 2009-07-08

Family

ID=39671954

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101301A AR065875A1 (es) 2007-03-30 2008-03-28 Metodos de separacion y detecion de acetato de bacedoxifeno en composiciones farmaceuticas

Country Status (17)

Country Link
US (1) US20080249303A1 (es)
EP (1) EP2132172A1 (es)
JP (1) JP2010523982A (es)
KR (1) KR20090127431A (es)
CN (1) CN101657421A (es)
AR (1) AR065875A1 (es)
AU (1) AU2008232666A1 (es)
BR (1) BRPI0809950A2 (es)
CA (1) CA2682185A1 (es)
CL (1) CL2008000922A1 (es)
IL (1) IL201043A0 (es)
MX (1) MX2009010508A (es)
PA (1) PA8773701A1 (es)
PE (1) PE20090100A1 (es)
RU (1) RU2009135267A (es)
TW (1) TW200902023A (es)
WO (1) WO2008121800A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833645C (en) * 2011-05-17 2019-09-17 Zach System S.P.A. Method of detecting polymorphs using synchrotron radiation
CN106198827B (zh) * 2016-08-11 2018-03-27 齐鲁制药有限公司 高效测定醋酸巴多昔芬及其杂质的药物分析方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1553781A (en) * 1976-08-05 1979-10-10 Exxon Research Engineering Co Bisphenol derivatives and their use as stabilizers
ATE76435T1 (de) * 1985-06-26 1992-06-15 Upjohn Co Solubilisation und oxidation von somatotropin aus transformierten mikroorganismen.
US5298397A (en) * 1989-10-19 1994-03-29 Yamasa Shoyu Kabushiki Kaisha Method of assaying d-vanillylmandelic acid
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
WO2003087796A1 (en) * 2002-04-10 2003-10-23 Bristol-Myers Squibb Company High throughput x-ray diffraction filter sample holder
PA8629201A1 (es) * 2004-04-07 2005-11-25 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno
US7683051B2 (en) * 2004-04-07 2010-03-23 Wyeth Crystalline polymorph of bazedoxifene acetate
KR20080031037A (ko) * 2005-06-29 2008-04-07 와이어쓰 결합형 에스트로겐과 바제독시펜의 제형

Also Published As

Publication number Publication date
AU2008232666A1 (en) 2008-10-09
PA8773701A1 (es) 2008-11-19
EP2132172A1 (en) 2009-12-16
CA2682185A1 (en) 2008-10-09
BRPI0809950A2 (pt) 2014-10-07
PE20090100A1 (es) 2009-02-26
IL201043A0 (en) 2010-05-17
KR20090127431A (ko) 2009-12-11
US20080249303A1 (en) 2008-10-09
TW200902023A (en) 2009-01-16
MX2009010508A (es) 2009-10-19
JP2010523982A (ja) 2010-07-15
RU2009135267A (ru) 2011-05-10
WO2008121800A1 (en) 2008-10-09
CN101657421A (zh) 2010-02-24
CL2008000922A1 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
WO2008122965A3 (en) Pharmaceutical cyclosporin compositions
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
MY175260A (en) Prion free nanoparticle compositions and methods of making thereof
MX2012001365A (es) Estructuras fibrosas.
TW200833736A (en) Polytrimethylene ether glycol esters
NO20081101L (no) Regioselektiv metode for fremstilling av benzimidazol-tiofener
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201070919A1 (ru) Цельные интравагинальные кольца, содержащие прогестерон, и способы изготовления и применения таких колец
WO2009080555A3 (en) Carboxyl- or hydroxyl- substituted benzimidazole derivatives
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
EA200900496A1 (ru) Сульфонамидные соединения (варианты), содержащая их фармацевтическая композиция, способ ингибирования растворимой эпоксидгидролазы и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой
MX2011001679A (es) Derivados de flavina.
HK1197191A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
BRPI0922774A2 (pt) Composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.
EA201390638A1 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
UA109154C2 (uk) Спосіб відокремлення інбредного насіння і машина для його здійснення
EA201290582A1 (ru) ЛИГАНДЫ НЕЙРОНАЛЬНОГО НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА αβ
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
WO2013022922A3 (en) Fibrous structures
BR112015024490A2 (pt) aparelho para reduzir o artefato de movimento em um sinal de ecg de um paciente e método para reduzir artefato de movimento em um sinal de ecg de um paciente
AR065875A1 (es) Metodos de separacion y detecion de acetato de bacedoxifeno en composiciones farmaceuticas
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE602004010680D1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
SG156633A1 (en) Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FB Suspension of granting procedure